Disclaimers Content and Educational Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment
How Peptide Therapy Fits In Peptides are short chains of amino acids
The consequences of these risks could be severe and maybe even life threatening for some
By combining in vitro experiments with inhibitors, gene silencing, functional assays, and transcriptomic data analysis, the researchers established a framework to uncover how Humanin might regulate insulin signaling, lipid metabolism, apoptosis, and mitochondrial function
Cerebrolysin's Position: Decades of clinical use across 40+ countries with established safety and efficacy data Meta-analyses and Cochrane systematic reviews the highest levels of clinical evidence Known limitations: complex mixture makes precise mechanism attribution difficult, not FDA-approved, requires IV/IM administration Represents validated but incrementally effective neurotrophic therapy Dihexa's Position: Exceptional mechanistic novelty HGF/c-Met potentiation at picomolar concentrations is a genuinely unique pharmacological finding if confirmed Entirely preclinical with no human data of any kind Foundational research compromised by expression of concern and retraction the core evidence base is actively questioned Theoretical safety concerns (c-Met oncogenesis) that have not been addressed experimentally Represents frontier neuroscience that has not survived the basic tests of scientific reproducibility For Researchers: Cerebrolysin offers a clinically validated tool for studying neurotrophic effects in humans, supported by the strongest available evidence
Wilson's disease or other copper-handling disorders: GHK-Cu delivers bioavailable copper
